STOCK TITAN

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags

Roivant (Nasdaq: ROIV) has been recognized on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List, ranking 28th place in the small & medium category. This marks the company's first appearance on this prestigious list.

The selection process involved analyzing survey responses from nearly 40,000 employees across Great Place To Work Certified companies in the biotech and pharmaceutical industry. The evaluation was based on the Trust Index Survey, which considered data from over 1.3 million survey responses representing more than 8.4 million employees.

Roivant (Nasdaq: ROIV) è stata inserita nella lista Best Workplaces in BioPharma 2025 di Fortune Media e Great Place To Work, classificandosi al 28° posto nella categoria piccole e medie imprese. È la prima apparizione dell'azienda in questa prestigiosa classifica. Il processo di selezione ha analizzato le risposte di quasi 40.000 dipendenti di aziende certificate Great Place To Work nel settore biotecnologico e farmaceutico. La valutazione si è basata sul Trust Index Survey, che ha considerato dati da oltre 1,3 milioni di risposte e che rappresentano più di 8,4 milioni di dipendenti.

Roivant ( Nasdaq: ROIV) ha sido reconocido en Fortune Media y Great Place To Work en la lista Best Workplaces in BioPharma 2025, ocupando el puesto 28 en la categoría de pequeñas y medianas empresas. Es la primera aparición de la compañía en esta prestigiosa lista. El proceso de selección analizó las respuestas de casi 40.000 empleados de empresas certificadas por Great Place To Work en la industria biotecnológica y farmacéutica. La evaluación utilizó el Trust Index Survey, con datos de más de 1,3 millones de respuestas que representan a más de 8,4 millones de empleados.

Roivant (나스닥: ROIV)가 Fortune Media와 Great Place To Work의 2025년 바이오제약 분야 Best Workplaces 목록에 선정되어 중소기업 부문 28위를 차지했습니다. 이는 이 회사의 이 명망 있는 목록에 처음 이름을 올린 것입니다. 선정 과정은 생명공학 및 제약 산업의 Great Place To Work 인증 기업에서 근무하는 거의 40,000명의 직원 설문 응답을 분석했습니다. 평가의 기초가 된 Trust Index 설문은 1,300,000건이 넘는 응답 데이터를 고려했고, 이는 8,400,000명 이상의 직원을 대표합니다.

Roivant (Nasdaq : ROIV) a été reconnu sur Fortune Media et Great Place To Work dans la liste des Best Workplaces in BioPharma 2025, se classant à la 28e place dans la catégorie petites et moyennes entreprises. C’est la première apparition de l’entreprise sur cette liste prestigieuse. Le processus de sélection a analysé les réponses de près de 40 000 employés issus d’entreprises certifiées Great Place To Work dans l’industrie biotechnologique et pharmaceutique. L’évaluation s’est basée sur l’enquête Trust Index, qui a pris en compte des données provenant de plus de 1,3 million de réponses et représentant plus de 8,4 millions d’employés.

Roivant (Nasdaq: ROIV) wurde in Fortune Media und Great Place To Work's 2025 Best Workplaces in BioPharma-Liste aufgenommen und belegt Platz 28 in der Kategorie Klein- & Mittelunternehmen. Dies markiert den ersten Auftritt des Unternehmens auf dieser renommierten Liste. Der Auswahlprozess analysierte die Antworten von fast 40.000 Mitarbeitenden von Great Place To Work-zertifizierten Unternehmen in der Biotechnologie- und Pharmaindustrie. Die Bewertung basierte auf dem Trust Index Survey, der Daten aus über 1,3 Millionen Umfragen berücksichtigt, die mehr als 8,4 Millionen Mitarbeitende repräsentieren.

تم الاعتراف بشركة Roivant (الرمز Nasdaq: ROIV) ضمن قائمة Fortune Media وGreat Place To Work لأفضل بيئة عمل في مجال البيوفارما لعام 2025، حيث احتلت المركز الثامن والعشرين في فئة الشركات الصغيرة والمتوسطة. وهذه هي الظهور الأول للشركة في هذه القائمة المرموقة. تضمنت عملية الاختيار تحليل ردود من نحو 40,000 موظف لدى الشركات المعتمدة من Great Place To Work في صناعة التكنولوجيا الحيوية والصيدلانية. واستند التقييم إلى استبيان Trust Index الذي أخذ في الاعتبار بيانات من أكثر من 1.3 مليون استجابة تمثل أكثر من 8.4 ملايين موظف.

Roivant(纳斯达克股票代码:ROIV)入选 Fortune Media 与 Great Place To Work 联合评选的 2025 年生物制药领域最佳工作场所名单,在中小型企业类别中位列第 28 位。这也是该公司首次出现在这一享有盛誉的榜单上。评选过程分析了来自在生物技术和药品行业中获得 Great Place To Work 认证的公司近 4 万名员工的问卷回答。评估基于 Trust Index 调查,涵盖超过 130 万份问卷数据,代表超过 840 万名员工

Positive
  • None.
Negative
  • None.

BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List. This is Roivant’s first time being named to this prestigious list, coming in at 28th place in the small & medium category. Earning a spot means that Roivant is one of the best companies to work for in the country.

The Best Workplaces in BioPharma award is based on analysis of survey responses from nearly 40,000 employees at Great Place To Work Certified™ companies in the biotechnology and pharmaceutical industry.

“We are incredibly honored to be named one of the Best Workplaces in BioPharma by Fortune and Great Place To Work,” said Matt Gline, CEO of Roivant. “This recognition reflects our team's commitment to creating an empowering, high-performance, and talent-oriented culture. It's our people who make Roivant a great place to work, and we are proud to celebrate this achievement together.”

The Best Workplaces in BioPharma list is highly competitive. Great Place To Work, the global authority on workplace culture, determines its lists using its proprietary Trust Index™ Survey to evaluate and certify thousands of organizations in America’s largest ongoing annual workforce study, based on over 1.3 million survey responses and data from companies representing more than 8.4 million employees.

Survey responses reflect a comprehensive picture of the workplace experience. Honorees were selected based on their ability to offer positive outcomes for employees regardless of job role, race, gender, sexual orientation, work status, or other demographic identifier.

About the Fortune Best Workplaces in BioPharma List

Great Place To Work selected the 2025 Fortune Best Workplaces in BioPharma by analyzing over 1.3 million confidential employee surveys, representing the experiences of 8.4 million workers in the U.S. in 2024 and 2025. Of those responses, nearly 40,000 came from employees at Great Place To Work Certified companies in the biotechnology and pharmaceutical industry, and this list is based on that feedback. Company rankings are derived from 60 employee experience questions within the Great Place To Work Trust Index™ Survey. Companies with 10 to 999 employees competed in the small and medium category. Companies with 1,000 or more employees were considered for the large category. Read the full methodology.

To get on this list next year, start here.

About Great Place To Work

As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified and receiving recognition on a coveted Best Workplaces™ List.

Follow Great Place To Work on LinkedIn, X, and Instagram or visit greatplacetowork.com and sign up for the newsletter to learn more.

About Fortune

Fortune upholds a legacy of award-winning writing and trusted reporting for executives who want to make business better. Independently owned, with a global perspective and digital agility, Fortune tells the stories of a new generation of innovators, builders, and risk takers. Online and in print, Fortune measures corporate performance through rigorous benchmarks and holds companies accountable. Fortune creates communities by convening true thought leaders and iconoclasts — those who shape industry, commerce, and society — through powerful and prestigious lists, events, and conferences, such as the iconic Fortune 500, the CEO Initiative, and Most Powerful Women. For more information, visit fortune.com.

About Roivant

Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com.



Contacts:

Media
Stephanie Lee
stephanie.lee@roivant.com

FAQ

What ranking did Roivant achieve on the 2025 Fortune Best Workplaces in BioPharma List?

Roivant ranked 28th place in the small & medium category on the 2025 Fortune Best Workplaces in BioPharma List, marking their first appearance on this prestigious list.

How many employees were surveyed for the 2025 Best Workplaces in BioPharma selection?

The selection process analyzed survey responses from nearly 40,000 employees at Great Place To Work Certified companies in the biotech and pharmaceutical industry.

Who is the CEO of Roivant (ROIV) in 2025?

Matt Gline is the CEO of Roivant, who expressed honor in the company being named one of the Best Workplaces in BioPharma.

What criteria were used to select companies for the 2025 Best Workplaces in BioPharma List?

Companies were selected based on Great Place To Work's Trust Index Survey, evaluating workplace experiences across various demographics, including job role, race, gender, sexual orientation, and work status.
Roivant Sciences

:ROIVW

ROIVW Rankings

ROIVW Latest News

ROIVW Stock Data